- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00721201
Glucocorticoid Receptor Antagonism in Subclinical Cushings
January 22, 2021 updated by: Sheffield Teaching Hospitals NHS Foundation Trust
A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings
The purpose of this study is to assess the effects of reducing the activity of endogenous glucocorticoid in patients with low-grade cortisol excess
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
6
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sheffield, United Kingdom
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients will be eligible for inclusion if: they are males and over 18, lack clinical features classically associated with Cushing's syndrome; have evidence of excess circulating cortisol
Exclusion Criteria:
- Evidence of local or systemic malignancy; overt Cushing's syndrome; severe uncontrolled diabetes mellitus or hypertension; pregnancy; clinically significantly impaired cardiovascular function (e.g. stage IV cardiac failure); severe liver disease (liver enzymes ≥ 3 x the institutional upper limit of normal range); significantly impaired renal function (eGFR <30/min); uncontrolled severe active infection; treatment with approved or experimental steroidogenesis inhibitors, adrenolytic agents, within four weeks of admission; In women, known endometrial cancer, history of endometrial hyperplasia or vaginal bleeding of unknown cause; requirement for inhaled or systemic glucocorticoids for existing disease; impaired mental capacity or markedly abnormal psychiatric evaluation that precludes informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood pressure
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glucose homeostasis
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Dr John Newell Price, University of Sheffield
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (ACTUAL)
March 1, 2010
Study Completion (ACTUAL)
March 1, 2010
Study Registration Dates
First Submitted
July 21, 2008
First Submitted That Met QC Criteria
July 22, 2008
First Posted (ESTIMATE)
July 23, 2008
Study Record Updates
Last Update Posted (ACTUAL)
January 26, 2021
Last Update Submitted That Met QC Criteria
January 22, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Abortifacient Agents
- Luteolytic Agents
- Abortifacient Agents, Steroidal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Menstruation-Inducing Agents
- Mifepristone
Other Study ID Numbers
- STH14791
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subclinical Cushing's
-
Prof. Dominique de Quervain, MDCompletedFear of Public Speaking (Subclinical)Switzerland
-
Oslo University HospitalUnknownSubclinical Sleep-Activated Epileptiform Activity | CSWSNorway
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Alexion...WithdrawnSubclinical Acute Antibody-mediated Rejection in Kidney Transplantation
-
Ain Shams Maternity HospitalUnknownIntra-amniotic Subclinical Infection.Egypt
-
University of MichiganRecruitingDepression | Subclinical Depressive SymptomsUnited States
-
VA Office of Research and DevelopmentCentral Arkansas Veterans Healthcare SystemCompletedSubclinical HypothyroidismUnited States
-
AbbottDimension ResearchCompletedSubclinical HypothyroidismPakistan
-
Centre Hospitalier Universitaire de NiceWithdrawnSubclinical hypothyroïdismFrance
-
Assaf-Harofeh Medical CenterCompleted
-
Riphah International UniversityCompletedSubclinical Spinal PainPakistan
Clinical Trials on Mifepristone
-
Corcept TherapeuticsCompletedPsychotic Disorders | Major Depressive DisorderUnited States
-
BioPro Medical LtdCompletedUterine Fibroid | Vaginal Bleeding.Israel
-
Corcept TherapeuticsRecruitingDiabetes Mellitus, Type 2 | HypercortisolismUnited States
-
Hadassah Medical OrganizationCompleted
-
VGX Pharmaceuticals, LLCCompletedHIV InfectionsUnited States
-
Cairo UniversityUnknown
-
University of ManitobaManitoba HarvestCompletedDiabetes Prevention | Obesity PreventionCanada
-
Gynuity Health ProjectsCompletedInduced AbortionGeorgia, Vietnam
-
University Hospital Inselspital, BerneUnknownCesarean DeliverySwitzerland
-
Planned Parenthood League of MassachusettsRecruiting